Erschienen in:
26.04.2016
Slow gait speed is an independent predictor of early death in older cancer outpatients: Results from a prospective cohort study
verfasst von:
Frédéric Pamoukdjian, V. Lévy, G. Sebbane, M. Boubaya, T. Landre, C. Bloch-Queyrat, E. Paillaud, L. Zelek
Erschienen in:
The journal of nutrition, health & aging
|
Ausgabe 2/2017
Einloggen, um Zugang zu erhalten
Abstract
Objective
To assess the predictive value of gait speed for early death in older outpatients with cancer.
Design
Prospective bicentric observational cohort study.
Setting
The Physical Frailty in Elder Cancer patients (PF-EC) study (France).
Participants
One hundred and ninety outpatients with cancer during the first 6 months of follow up in the PF-EC study.
Measurements
The association between usual gait speed over 4 m alone (GS) or included in the short physical performance battery (SPPB) and overall survival within 6 months following a comprehensive geriatric assessment (CGA). A Cox proportional-hazard regression model was performed in non-survivors for clinical factors from the CGA, along with c reactive protein (CRP). Two models were created to assess GS alone and from inclusion in the SPPB.
Results
The mean age was 80.6 years, and 50.5% of the participants were men. Death occurred in 11% (n=22) of the participants within the 6 month follow up period. Of these participants, 98% had solid cancers, and 33% had a metastatic disease. A GS < 0.8 m/s (HR=5.6, 95%CI=1.6-19.7, p=0.007), a SPPB < 9 (HR=5.8, 95%CI=1.6-20.9, p=0.007) and a CRP of 50 mg/l or greater (p<0.0001) were significantly associated with early death in the two multivariate analyses. Cancer site and extension were not significantly associated with early death.
Conclusion
Walking tests are associated with early death within the 6 month follow up period after a CGA independent of cancer site and cancer extension. GS alone < 0.8 m/s is at least as efficacious as the SPPB in predicting this outcome. GS alone could be used routinely as a marker of early death to adapt oncologic therapeutics. Further studies are needed to validate these preliminary data.